{"protocolSection":{"identificationModule":{"nctId":"NCT06010628","orgStudyIdInfo":{"id":"Y (2023) 144"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)","officialTitle":"Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2): a Prospective, Randomized, Open Label, Blinded Endpoint, and Multi-center Study"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-02-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-03-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-03-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-08-20","studyFirstSubmitQcDate":"2023-08-20","studyFirstPostDateStruct":{"date":"2023-08-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-31","lastUpdatePostDateStruct":{"date":"2024-02-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Director","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"General Hospital of Shenyang Military Region","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To date, the benefit of intravenous thrombolysis is confined within 4.5 hours of onset for acute ischemic stroke (AIS) patients without advanced neuroimaging selection. Unpublished pilot EXIT-BT (EXtending the tIme window of Thrombolysis by ButylphThalide up to 6 Hours after onset) suggest the safety, feasibility and potential benefit of intravenous tenecteplase (TNK) in AIS within 4.5 to 6 hours of onset. The current study aims to investigate the efficacy and safety of TNK for AIS within 4.5 to 6 hours of onset."},"conditionsModule":{"conditions":["Stroke, Ischemic"],"keywords":["thrombolysis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1250,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Tenecteplase group","type":"EXPERIMENTAL","description":"intravenous thrombolysis with tenecteplase","interventionNames":["Drug: Tenecteplase"]},{"label":"Control group","type":"OTHER","description":"standard stroke care based on national guideline","interventionNames":["Drug: Tenecteplase"]}],"interventions":[{"type":"DRUG","name":"Tenecteplase","description":"intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).","armGroupLabels":["Control group","Tenecteplase group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"proportion of modified Rankin Scale (mRS) 0-1","description":"The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome","timeFrame":"90±7 days"}],"secondaryOutcomes":[{"measure":"proportion of modified Rankin Scale (mRS) 0-2","description":"The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome","timeFrame":"90±7 days"},{"measure":"ordinal distribution of modified Rankin Scale (mRS)","description":"The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome","timeFrame":"90±7 days"},{"measure":"change in National Institute of Health stroke scale (NIHSS) score","description":"the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome.","timeFrame":"24 (-6/+12) hours"},{"measure":"change in National Institute of Health stroke scale (NIHSS) score","description":"the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome.","timeFrame":"10±2 days"},{"measure":"occurrence of early neurological improvement (ENI)","description":"ENI is defined as more than 4-point decrease in National Institute of Health stroke scale score","timeFrame":"24 (-6/+12) hours"},{"measure":"new stroke or other vascular event(s)","timeFrame":"90±7 days"},{"measure":"all-cause mortality","timeFrame":"90±7 days"},{"measure":"symptomatic intracranial hemorrhage (sICH)","description":"sICH is defined as parenchymal hematoma type 1 or 2 (PH1 or PH2), remote intraparenchymal hematoma (RIH), subarachnoid hemorrhage, or intraventricular hemorrhage on head CT/MRI scan causally associated with clinically significant neurological deterioration (NIHSS score ≥4 point increase) in the opinion of the clinical investigator or independent safety monitor.","timeFrame":"24 (-6/+12) hours"},{"measure":"intracranial hemorrhage","description":"any evidence of bleeding on the head CT scan, classified by the Heidelberg Bleeding Classification","timeFrame":"24 (-6/+12) hours"},{"measure":"major systemic bleeding event","timeFrame":"24 (-6/+12) hours"},{"measure":"any bleeding event","timeFrame":"24 (-6/+12) hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18 year\n* Acute ischemic stroke confirmed by non-contrast computed tomography;\n* The time from last known well to treatment: 4.5 - 6 hours;\n* NIHSS ≥ 4 at randomization;\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pre-stroke disability (mRS≥2);\n* Planned intravenous thrombolysis based on WAKE-UP or EXTEND study criterion;\n* Any contraindication to intravenous thrombolysis: Obvious head injury or stroke within 3 months; Subarachnoid or intracranial hemorrhage; History of intracranial hemorrhage; Intracranial tumor, arteriovenous malformation or aneurysm; Intracranial or spinal cord surgery within 3 months; Myocardial infarction within 3 months; Major surgery within 1 month; Gastrointestinal or urinary tract hemorrhage within the previous 30 days; Arterial puncture at a noncompressible site within the previous seven days; Active internal hemorrhage; Coagulation abnormalities: platelet count of \\<100000/mm3; Aortic arch dissection; Heparin therapy within 24 hours; Infective endocarditis; Oral warfarin is being taken and INR\\>1.6 or APTT abnormal; Systolic pressure ≥185 mmHg or diastolic pressure ≥110 mmHg; Blood glucose \\< 50 mg/dl (2.7mmol/L); Neurological deficit after epileptic seizures;\n* Pregnancy;\n* Allergy to test drugs;\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Hui-Sheng Chen","status":"RECRUITING","city":"ShenYang","state":"None Selected","zip":"110840","country":"China","contacts":[{"name":"Yi-Han Wang","role":"CONTACT","phone":"+862428897524","email":"wangyihan34732512@163.com"}],"geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Department of Neurology, General Hospital of Northern Theater Command","status":"RECRUITING","city":"Shenyang","zip":"110016","country":"China","contacts":[{"name":"Hui-Sheng Chen, Ph.D.","role":"CONTACT","phone":"+86 13352452086","email":"chszh@aliyun.com"}],"geoPoint":{"lat":41.79222,"lon":123.43278}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077785","term":"Tenecteplase"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M1911","name":"Tenecteplase","asFound":"Early Intervention","relevance":"HIGH"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}